Sunday, November 26, 2017 6:41:35 PM
I suppose its also possible that the trial has not met all primary (PFS would be very long, as phase 1 trial data seemed to indicate, being over 19 months on average per Kratz) or secondary endpoints (patients have not expired in overall survival follow-up call surveillance) and that is the reason they are not delivering an update... giving someone a chance to absorb shares inexpensively in separate corporate accounts... as a potential reason.
Hopefully someday we will find out, because an update is overdue. I would have assumed that if the company gave a 1H 2017 timeline they would have provided an update of what they did have, endpoints reached or not... wouldn't be that hard... so they are probably being baboonfaced as you say not by the CRO but likely by the suitor who wants "sumfin" fer 'nuffin'
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM